ADIPOQ and metabolic syndrome: Crude prevalence rates of metabolic syndrome were higher according to increased adiponectin levels in chronic kidney disease stage 1 [Q1 vs. Q4, 21 (45.7%) vs. 2 (4.3%)], 2 [47 (51.1%) vs. 6 (6.5%)], and stage 3 [80 (35.4%) vs. 32 (14.2%)] groups, but these correlations were blunted in stage 4 group.